Efficacy of anakinra in refractory Behçet's disease sacroiliitis

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages S171-

  Caso, F ^a,b   Rigante, D ^c   Vitale, A ^a   Lucherini, O M ^a   Cantarini, Luca ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; INFLIXIMAB; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; BEHCET DISEASE; BONE MARROW EDEMA; CASE REPORT; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; GENITAL ULCER; HUMAN; LABORATORY DIAGNOSIS; LETTER; MALE; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PSEUDOFOLLICULITIS; SACROILIITIS; SKIN DISEASE; UVEITIS; BEHCET SYNDROME; FEMALE;

BEHCET SYNDROME; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; UVEITIS;

EID: 84907562404     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. EMMI G, SILVESTRI E, CAMELI AM et al.: Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol 2013; 31 (Suppl. 77): S152-3.
2. INTERNATIONAL STUDY GROUP FOR BEHçET'S DISEASE: Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
3. HATEMI G, SILMAN A, BANG D et al.: EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656-62.
4. ZHOU ZY, CHEN SL, SHEN N, LU Y: Cytokines and Behçet's disease. Autoimmun Rev 2012; 11: 699-704.
5. GüL A, TUGAL-TUTKUN I, DINARELLO CA et al.: Interleukin-1ß-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Ann Rheum Dis 2012; 71: 563-6.
6. CANTARINI L, VITALE A, BORRI M et al.: Successful use of canakinumab in a patient with resistant Behçet's disease. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S115.
7. UGURLU S, UCAR D, SEYAHI E et al.: Canakin-umab in a patient with juvenile Behçet's syndrome with refractory eye disease. Ann Rheum Dis 2012; 71: 1589-91.
8. BOTSIOS C, SFRISO P, FURLAN A et al.: Resistant Behçet disease responsive to anakinra. Ann Intern Med 2008; 149: 284-6.
9. BILGINER Y, AYAZ NA, OZEN S: Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clin Rheumatol 2010; 29: 209-10.
10. CANTARINI L, VITALE A, SCALINI P et al.: Anakinra treatment in drug-resistant Behçet's Disease: a case series. Clin Rheumatol 2013 Dec 5. [Epub ahead of print].